Shots:

• The ODD designation follows two P-II studies assessing ACE-083 (Myostatin+ muscle agent) in patients with CMT and facioscapulohumeral muscular dystrophy (FSHD)
• The two P-II studies demonstrated in elevation in muscle volume in target muscles with its expected results in H2’19 for CMT & FSHD
• ACE-083 is a long acting Myostatin+ muscle agent targeting TGF-beta superfamily ligands and has receives FDA’s FT designation for CMT and FDA’s FT & ODD for FSHD in 2018

Ref: Ascendis Pharma | Image: Cape Business News